![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors.
Lead Product(s): OKI-219,Fulvestrant
Therapeutic Area: Oncology Product Name: OKI-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: OnKure Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 13, 2024
Details:
The combined company will advance OnKure’s pipeline targeting oncogenic mutations in PI3K alpha, including its lead program OKI-219, which is in Phase 1 trial for the treatment of solid tumors.
Lead Product(s): OKI-219,Fulvestrant
Therapeutic Area: Oncology Product Name: OKI-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: OnKure Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 13, 2024
Details:
REN001 (mavodelpar) is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist which is being evaluated for the treatment of primary mitochondrial myopathies (PMM).
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
The proceeds will provide vTv with important financial support for preparing the launch of the TTP399 (cadisegliatin), a potential adjunctive therapy to insulin, phase 3 program in the treatment of type 1 diabetes.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: vTv Therapeutics
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Agreement November 01, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPAR delta agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
The net proceeds will be used to fund the development of company's lead product, REN001 (mavodelpar), a potent and selective agonist of the peroxisome proliferator-activated receptor delta, in adult patients with PMM due to mitochondrial DNA, or mtDNA, defects.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
REN001 (mavodelpar) is a potent and selective peroxisome PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and PMM and LC-FAOD.
Lead Product(s): Mavodelpar
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases : primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
Lead Product(s): REN001
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
REN001 is a potent and selective PPARδ agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Lead Product(s): REN001
Therapeutic Area: Genetic Disease Product Name: REN001
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022